Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 11/2007

01-11-2007 | Letter to the Editor

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Authors: Patrick Terheyden, Maja Ann Hofmann, M. Weininger, Eva-B. Bröcker, Jürgen C. Becker

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2007

Login to get access

Abstract

Purpose

The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated.

Methods

We tested this notion in three patients with advanced and therapy-refractory melanoma.

Results

Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis.

Conclusion

Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.
Literature
Beierle EA, Nagaram A, Dai W, Iyenger M, Chen MK (2005) VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res 127:21–28PubMedCrossRef
Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline of angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastastic melanoma. Melanoma Res 15:515–522PubMedCrossRef
Demirkesen C, Buyukpinarbasili H, Ramazanoglu R, Oguz O, Mandel NM, Kaner G (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblast growth factor. Pathology 38:132–137PubMedCrossRef
Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759PubMedCrossRef
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400PubMedCrossRef
Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680PubMed
Giatromanolaki A, Sivridis E, Koukourakis MI (2006) Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29:408–417PubMedCrossRef
Gille J (2006) Antiangionenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15:175–186PubMedCrossRef
Güven K, Kittler H, Wolff K, Pehamberger H (2001) Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine resistant melanoma patients. Melanoma Res 11:411–415PubMedCrossRef
Hicklin DJ, Ellis LM (2005) Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRef
Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Götz R, Rapp UR (2004) Constitutive activation of the Ras-Raf signaling pathway in metastastic melanoma is associated with poor prognosis. J Carcinog 3:6PubMedCrossRef
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluororuracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
Lev DC, Ruiz M, Mills L, McGary EC, Price JC, Bar-Eli M (2003) Dacarbazine causes transcriptional up-regulation of interleukin-8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753–763PubMed
Passagne I, Evrard A, Depeille P, Cuq P, Cupissol D, Vian L (2006) O6-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211:97–105PubMedCrossRef
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRef
Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802PubMedCrossRef
Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRef
Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731–3736PubMedCrossRef
Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RE, Kerbel RS (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781–788PubMedCrossRef
Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577–583PubMed
Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497–504PubMedCrossRef
Zhang L, Hannay JAF, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D (2006) Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumour growth, metastasis , and chemoresistance. Cancer Res 66:8770–8778PubMedCrossRef
Metadata
Title
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
Authors
Patrick Terheyden
Maja Ann Hofmann
M. Weininger
Eva-B. Bröcker
Jürgen C. Becker
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/2007
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0251-8

Other articles of this Issue 11/2007

Journal of Cancer Research and Clinical Oncology 11/2007 Go to the issue

Original Paper

Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia

Review

Protein kinase C family: On the crossroads of cell signaling in skin and tumor epithelium

Original Paper

Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification

Original Paper

CXCL5 overexpression is associated with late stage gastric cancer

Original Paper

Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast–ovarian cancer families from Kerala, South India

Original Paper

Importance of polymorphisms in NF-κB1 and NF-κBIα genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits